Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - perindopril arginine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: hydrophobic colloidal silica anhydrous; magnesium stearate; sodium starch glycollate; macrogol 6000; lactose monohydrate; maltodextrin; colour - apx-perindopril arginine is indicated for: the treatment of hypertension; and the treatment of heart failure. in such patients it is recommended that apx-perindopril arginine be given with a diuretic and/or digoxin under close medical supervision. (the safety and efficacy of apx-perindopril arginine has not been demonstrated for new york heart association category iv patients); and patients with established coronary artery disease (see clinical trials) who are stable on concomitant therapy and have no heart failure, to reduce the risk of non-fatal myocardial infarction or cardiac arrest.

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories australia pty ltd - perindopril erbumine -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories australia pty ltd - perindopril erbumine -

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories australia pty ltd - perindopril erbumine -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - perindopril erbumine -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - perindopril erbumine -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - perindopril erbumine -

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - perindopril erbumine -

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - perindopril erbumine (unii: 1964x464oj) (perindoprilat - unii:2uv6znq92k) - perindopril erbumine 2 mg - perindopril erbumine is indicated for the treatment of patients with essential hypertension. perindopril erbumine may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. perindopril erbumine is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. perindopril erbumine can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. perindopril erbumine is contraindicated in patients known to be hypersensitive (including angioedema) to this product or to any other ace inhibitor. perindopril erbumine is also contraindicated in patients with hereditary or idiopathic angioedema. do not co-administer aliskiren with perindopril erbumine in patients with diabetes [see drug interactions (7.8) ]. perindopril erbumine is contraindicated in combination with neprilysin inhibitor (e.g., sacubitril).

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc - perindopril erbumine (unii: 1964x464oj) (perindopril - unii:y5gmk36kgy) - perindopril erbumine 2 mg - stable coronary artery disease perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. hypertension perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. when using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (see warnings .) in considering use of